Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells

Tumor-associated macrophages (TAMs) represent the main immune cell population in various brain malignancies, but there is rare knowledge on the functional and, in particular, the prognostic role of TAMs in the meningioma (MGM) microenvironment. Here, we investigated TAM frequencies, activation state, survival-associated changes, and their association with tumor-infiltrating T lymphocytes (TILs) in two independent study samples comprising altogether 680 MGMs. To this end, we performed tissue cytometry analyses, quantified tissue cytokine levels, and integrated previously published TIL infiltration and microarray datasets in the discovery cohort comprising n = 195 clinically well-annotated cases. This was complemented by a DNA methylation-based deconvolution approach to predict TAM and TIL infiltration rates using immune cell-specific CpG sites as well as survival associations in an independent validation cohort of n = 485 MGMs. Our findings revealed substantial but heterogeneous TAM infiltration in newly diagnosed MGMs, with increased numbers of pro-tumoral TAMs in clinically aggressive tumors. Additional cytokine and transcriptome analyses corroborated the presence of an immunosuppressive niche in TAM-enriched MGMs. Importantly, a high frequency of pro-tumoral TAMs was associated with poor patient outcome, and high TAM infiltration was further identified as an independent prognostic factor for inferior survival, counteracting the beneficial prognostic effect of TILs. Moreover, methylation-based deconvolution analyses confirmed the opposing prognostic roles of TAMs and TILs in the validation cohort. Altogether, higher numbers of TAMs appear to be a hallmark of clinically aggressive behavior in newly diagnosed and recurrent MGMs. Unlike TILs, immunosuppressive TAMs seem to play a dominant role in the immunological landscape of MGMs with a significant negative impact on patient outcome, highlighting pro-tumoral TAMs to be an attractive treatment target in MGMs. Furthermore, our deconvolution approach presents a pipeline to computationally determine TAM and TIL infiltrates in the MGM microenvironment, which might be highly valuable for patient stratification for future immunotherapeutic treatments.

Authors

Institutions

Publication Details

Journal
Acta Neuropathologica
Published
2025-10-09
DOI
https://doi.org/10.1007/s00401-025-02948-6
Citations
2
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
3.25

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells

Sybren L. N. Maas, Sandro M. Krieg, David Ronan Raleigh, Ralf Ketter et al.
2 citations
Acta Neuropathologica
Glioma Diagnosis and Treatment
3.25
article

Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells

Sybren L. N. Maas, Sandro M. Krieg, David Ronan Raleigh, Ralf Ketter, Andreas Unterberg, Rolf Warta, Katrin Lamszus, Christel C. Herold‐Mende, Matthias Simon, Catharina Lotsch, Niels Grabe, Philipp Sievers, Andreas von Deimling, Almuth F. Keßler, Christian Senft, Christian Rommel, M. Barthel, Gerhard Jungwirth, Felix Sahm, Manfred Westphal, Mario Loehr, Fang Liu
article en
2 citations

Abstract

Tumor-associated macrophages (TAMs) represent the main immune cell population in various brain malignancies, but there is rare knowledge on the functional and, in particular, the prognostic role of TAMs in the meningioma (MGM) microenvironment. Here, we investigated TAM frequencies, activation state, survival-associated changes, and their association with tumor-infiltrating T lymphocytes (TILs) in two independent study samples comprising altogether 680 MGMs. To this end, we performed tissue cytometry analyses, quantified tissue cytokine levels, and integrated previously published TIL infiltration and microarray datasets in the discovery cohort comprising n = 195 clinically well-annotated cases. This was complemented by a DNA methylation-based deconvolution approach to predict TAM and TIL infiltration rates using immune cell-specific CpG sites as well as survival associations in an independent validation cohort of n = 485 MGMs. Our findings revealed substantial but heterogeneous TAM infiltration in newly diagnosed MGMs, with increased numbers of pro-tumoral TAMs in clinically aggressive tumors. Additional cytokine and transcriptome analyses corroborated the presence of an immunosuppressive niche in TAM-enriched MGMs. Importantly, a high frequency of pro-tumoral TAMs was associated with poor patient outcome, and high TAM infiltration was further identified as an independent prognostic factor for inferior survival, counteracting the beneficial prognostic effect of TILs. Moreover, methylation-based deconvolution analyses confirmed the opposing prognostic roles of TAMs and TILs in the validation cohort. Altogether, higher numbers of TAMs appear to be a hallmark of clinically aggressive behavior in newly diagnosed and recurrent MGMs. Unlike TILs, immunosuppressive TAMs seem to play a dominant role in the immunological landscape of MGMs with a significant negative impact on patient outcome, highlighting pro-tumoral TAMs to be an attractive treatment target in MGMs. Furthermore, our deconvolution approach presents a pipeline to computationally determine TAM and TIL infiltrates in the MGM microenvironment, which might be highly valuable for patient stratification for future immunotherapeutic treatments.

Acta NeuropathologicaVol. 150(1)
Universität Hamburg (DE), German Cancer Research Center (DE), University of California, San Francisco (US), Heidelberg University (DE), University Hospital Bonn (DE), Leiden University Medical Center (NL), University Hospital Heidelberg (DE), Evangelisches Krankenhaus Bielefeld (DE), University Medical Center Hamburg-Eppendorf (DE), Universitätsklinikum Würzburg (DE), Erasmus MC Cancer Institute (NL), Neurological Surgery (US), Deutsches Konsortium für Translationale Krebsforschung (DE), Friedrich Schiller University Jena (DE), Saarland University (DE)
Deutsches Krebsforschungszentrum, Deutsche Krebshilfe
Openalex Percentile: Top 7%
Glioma Diagnosis and Treatment
3.25
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.